A detailed history of Vise Technologies, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Vise Technologies, Inc. holds 33,255 shares of BMY stock, worth $1.94 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
33,255
Previous 33,767 1.52%
Holding current value
$1.94 Million
Previous $1.4 Million 22.68%
% of portfolio
0.22%
Previous 0.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $20,305 - $26,496
-512 Reduced 1.52%
33,255 $1.72 Million
Q2 2024

Aug 01, 2024

SELL
$40.25 - $52.99 $217,752 - $286,675
-5,410 Reduced 13.81%
33,767 $1.4 Million
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $291,046 - $329,990
6,066 Added 18.32%
39,177 $2.12 Million
Q4 2023

Feb 07, 2024

BUY
$48.48 - $57.85 $317,107 - $378,396
6,541 Added 24.62%
33,111 $1.7 Million
Q3 2023

Oct 31, 2023

BUY
$57.89 - $64.73 $55,748 - $62,334
963 Added 3.76%
26,570 $1.54 Million
Q2 2023

Aug 08, 2023

SELL
$63.71 - $70.74 $94,864 - $105,331
-1,489 Reduced 5.5%
25,607 $1.64 Million
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $376,124 - $426,609
5,724 Added 26.78%
27,096 $1.88 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $285,767 - $338,388
4,173 Added 24.26%
21,372 $1.54 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $41 - $24,281
316 Added 1.87%
17,199 $1.22 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $541,963 - $596,890
7,463 Added 79.23%
16,883 $1.3 Million
Q1 2022

Jun 08, 2022

BUY
$61.48 - $73.72 $579,141 - $694,442
9,420 New
9,420 $688,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Vise Technologies, Inc. Portfolio

Follow Vise Technologies, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vise Technologies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vise Technologies, Inc. with notifications on news.